Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
Hand-out
Press Releases
January 7, 2025

Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy

- RespiRx™ Nicotine Inhaler is the world's first truly inhalable nicotine replacement therapy -

bradford

The Bradford Era

Local & Social